CEL-SCI Corporation - Product Pipeline Review - 2012

Global Markets Direct, May 2012, Pages: 82

CEL-SCI Corporation – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “CEL-SCI Corporation - Product Pipeline Review - 2012” provides data on the CEL-SCI Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, CEL-SCI Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from CEL-SCI Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- CEL-SCI Corporation - Brief CEL-SCI Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of CEL-SCI Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of CEL-SCI Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the CEL-SCI Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate CEL-SCI Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of CEL-SCI Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the CEL-SCI Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with CEL-SCI Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of CEL-SCI Corporation and identify potential opportunities in those areas.

Keyword

Current R&D Portfolio of CEL-SCI Corporation; CEL-SCI Corporation - Key Therapeutics; CEL-SCI Corporation - Pipeline Overview and Promising Molecules; CEL-SCI Corporation - News; CEL-SCI Corporation - Latest Updates; CEL-SCI Corporation - Pipeline; CEL-SCI Corporation - Discontinued/Dormant Projects

List of Tables
List of Figures
CEL-SCI Corporation Snapshot
CEL-SCI Corporation Overview
Key Information
Key Facts
CEL-SCI Corporation – Research and Development Overview
Key Therapeutic Areas
CEL-SCI Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
CEL-SCI Corporation – Pipeline Products Glance
CEL-SCI Corporation – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
CEL-SCI Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
CEL-SCI Corporation – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
CEL-SCI Corporation – Drug Profiles
CEL-1000
Product Description
Mechanism of Action
R&D Progress
CEL-2000
Product Description
Mechanism of Action
R&D Progress
LEAPS-H1N1-DC
Product Description
Mechanism of Action
R&D Progress
Multikine
Product Description
Mechanism of Action
R&D Progress
Multikine + Cisplatin + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Multikine + Cyclophosphamide + Indomethacin + Zinc
Product Description
Mechanism of Action
R&D Progress
CEL-SCI Corporation – Pipeline Analysis
CEL-SCI Corporation – Pipeline Products by Therapeutic Class
CEL-SCI Corporation – Pipeline Products By Target
CEL-SCI Corporation – Pipeline Products by Route of Administration
CEL-SCI Corporation – Pipeline Products By Mechanism of Action
CEL-SCI Corporation – Recent Pipeline Updates
CEL-SCI Corporation - Dormant Projects
CEL-SCI Corporation – Company Statement
CEL-SCI Corporation – Locations And Subsidiaries
Head Office
CEL-SCI Corporation, Recent Developments
CEL-SCI Corporation- Press Release
Dec 01, 2009: CEL-SCI Corporation Retains Global Contract Research Organization (CRO) To Initiate Phase III Clinical Trial Of Multikine For Head And Neck Cancers
Oct 19, 2009: CEL-SCI Presents Data At American College Of Rheumatology Conference Which Suggests That CEL-2000 Has Potential To Slow Damage Caused By Rheumatoid Arthritis
Financial Deals Landscape
CEL-SCI Corporation, Deals Summary
CEL-SCI Corporation, Pharmaceuticals & Healthcare, Deal Details
Licensing Agreements
CEL-SCI Enters Into Licensing Agreement With IDC-GP Pharm For Multikine
CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine
CEL-SCI Enters Into Licensing Agreement With Byron Biopharma
CEL-SCI Enters Into Licensing Agreement With Orient Europharma
CEL-SCI Enters Into Licensing Agreement With Teva Pharma
Equity Offering
CEL-SCI Completes Private Placement Of Common Stock For $5.8 Million
CEL-SCI Completes Registered Direct Offering Of Common Stock For $4 Million
CEL-SCI Announces Private Placement Of $30 Million
CEL-SCI Announces Public Offering Of Upto $34 Million
CEL-SCI Completes Registered Direct Offering Of $20 Million
CEL-SCI Raises $10 Million Through Exercise Of Warrants
CEL-SCI Completes Registered Direct Offering Of $5 Million
CEL-SCI Completes Public Offering Of Units For $6 Million
CEL-SCI Completes Private Placement Of $0.75 Million
CEL-SCI Completes Private Placement Of $1 Million
CEL-SCI Completes Private Placement Of $15 Million
CEL-SCI Completes Private Placement Of $1 Million
CEL-SCI Completes Private Placement Of $0.5 Million
CEL-SCI Completes Private Placement Of $5.25 Million
Debt Offering
CEL-SCI Issues Convertible Notes For $8.3 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
CEL-SCI Corporation, Key Information
CEL-SCI Corporation, Key Facts
CEL-SCI Corporation – Pipeline by Indication, 2012
CEL-SCI Corporation – Pipeline by Stage of Development, 2012
CEL-SCI Corporation – Monotherapy Products in Pipeline, 2012
CEL-SCI Corporation – Combination Treatment Modalities in Pipeline, 2012
CEL-SCI Corporation – Phase III, 2012
CEL-SCI Corporation – Phase II, 2012
CEL-SCI Corporation – Phase I, 2012
CEL-SCI Corporation – Pre-Clinical, 2012
CEL-SCI Corporation – Pipeline By Therapeutic Class, 2012
CEL-SCI Corporation - Pipeline By Target, 2012
CEL-SCI Corporation – Pipeline By Route of Administration, 2012
CEL-SCI Corporation – Pipeline Products By Mechanism of Action, 2012
CEL-SCI Corporation – Recent Pipeline Updates, 2012
CEL-SCI Corporation - Dormant Developmental Projects,2012
CEL-SCI Corporation, Deals Summary
CEL-SCI Enters Into Licensing Agreement With IDC-GP Pharm For Multikine
CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine
CEL-SCI Enters Into Licensing Agreement With Byron Biopharma
CEL-SCI Enters Into Licensing Agreement With Orient Europharma
CEL-SCI Enters Into Licensing Agreement With Teva Pharma
CEL-SCI Completes Private Placement Of Common Stock For $5.8 Million
CEL-SCI Completes Registered Direct Offering Of Common Stock For $4 Million
CEL-SCI Announces Private Placement Of $30 Million
CEL-SCI Announces Public Offering Of Upto $34 Million
CEL-SCI Completes Registered Direct Offering Of $20 Million
CEL-SCI Raises $10 Million Through Exercise Of Warrants
CEL-SCI Completes Registered Direct Offering Of $5 Million
CEL-SCI Completes Public Offering Of Units For $6 Million
CEL-SCI Completes Private Placement Of $0.75 Million
CEL-SCI Completes Private Placement Of $1 Million
CEL-SCI Completes Private Placement Of $15 Million
CEL-SCI Completes Private Placement Of $1 Million
CEL-SCI Completes Private Placement Of $0.5 Million
CEL-SCI Completes Private Placement Of $5.25 Million
CEL-SCI Issues Convertible Notes For $8.3 Million

List of Figures
CEL-SCI Corporation – Pipeline by Indication, 2012
CEL-SCI Corporation – Pipeline by Stage of Development, 2012
CEL-SCI Corporation – Monotherapy Products in Pipeline, 2012
CEL-SCI Corporation – Combination Treatment Modalities in Pipeline, 2012
CEL-SCI Corporation – Pipeline By Therapeutic Class, 2012
CEL-SCI Corporation - Pipeline By Target, 2012
CEL-SCI Corporation – Pipeline By Route of Administration, 2012
CEL-SCI Corporation - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• SciQuest Inc,(SQI) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Scientific Games Corporation - Company Analysis
• Ixia - Company Analysis
• Altera Corporation
• SYNNEX Corporation
• Avocent Corporation - SWOT Analysis
• Bose Corporation
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis